CT-388 Obesity Drug Competitive Intelligence

What this research found

CT-388 is Roche/Carmot's dual GLP-1/GIP receptor agonist moving into Phase 3 for obesity. Benchmarking it against tirzepatide, retatrutide, and semaglutide across pipeline position, receptor pharmacology, placebo-adjusted weight loss, post-marketing safety, and patent life produced a positioning thesis — a balanced dual agonist that engages both receptors at equal potency where tirzepatide is roughly 9:1 GIPR-biased — plus a four-trial Phase III programme designed to turn that into a premium label.

• CT-388 is the only agent in the comparison set with balanced dual agonism: GLP-1R and GIPR half-maximal effective concentrations both at 0.030 nM, a ratio of 1.00, against tirzepatide's 0.054 nM and 0.006 nM (ratio 0.11) and retatrutide's 0.29.
• On a like-for-like basis restricted to standard-design, non-diabetic trials, CT-388's 16.9% placebo-adjusted weight loss at 24 weeks already clears semaglutide's 12.5% at 68 weeks, but trails tirzepatide's 18.6% at 72 weeks and retatrutide's 22.1% at 48 weeks.
• Tirzepatide, the closest approved analogue, triggered 3 of 6 adverse event disproportionality signals against semaglutide's 5 of 6. Its pancreatitis proportional reporting ratio is 2.2 times lower (3.93, 95% CI 3.73–4.15, versus 8.61, 8.21–9.04), and it showed no signal for thyroid neoplasm (0.99) or suicidal ideation (0.82).
• The exclusivity tail is the structural advantage. CT-388 compound patents are estimated to run to about 2041 in the US, roughly five years beyond tirzepatide (2036) and nine beyond semaglutide (2032), which would leave it the only branded dual agonist with full exclusivity after the tirzepatide cliff.
• The recommended BALANCE programme runs four trials and roughly 18,900 patients: 2,500 in non-diabetic obesity, 800 in type 2 diabetes, a 15,000-patient cardiovascular outcomes trial, and 600 in metabolic dysfunction-associated steatohepatitis, targeting a 2027–2028 US filing. GLP1R genetic links to cardiovascular disease (0.35) and heart failure (0.36) underpin the outcomes trial.

How it was done

Eight GLP-1 and GIP agonists were catalogued from ClinicalTrials.gov for development phase, mechanism, route, and trial count, and receptor potencies were assembled from curated literature values after the ChEMBL interface returned errors during the run. Placebo-adjusted weight loss was compared only within standard-design, non-diabetic trials, deliberately excluding intensive-lifestyle and run-in designs that would confound cross-drug comparison. Proportional reporting ratios for six safety signals in semaglutide and tirzepatide were computed from openFDA adverse event reports spanning January 2020 to April 2026, with a signal declared under the Evans criterion of ratio at or above 2, chi-square at or above 4, and at least three reports. Open Targets supplied genetic association scores for GLP1R and GIPR across six disease endpoints. Everything was synthesized into a SWOT analysis, a differentiation thesis, and a Phase III programme design, delivered as a 44-page report with 30 verified citations and six figures including a patent exclusivity Gantt chart running to 2048.

Data sources

• ClinicalTrials.gov API v2 — 8 GLP-1/GIP agonists with phase, mechanism, route, and trial counts
• openFDA FAERS — proportional reporting ratios for 6 signals across semaglutide and tirzepatide, January 2020 to April 2026
• Open Targets Platform v4 — GLP1R and GIPR association scores across 6 disease endpoints
• Curated literature potency values: Coskun et al. 2022 (tirzepatide), Urva et al. 2022 (retatrutide), Carmona et al. EASD 2023 (CT-388, estimated)
• Published trial results including semaglutide STEP-1 (Wilding et al., NEJM 2021), tirzepatide SURMOUNT-1 (Jastreboff et al., NEJM 2022), Davies et al., Lancet 2021, and Garvey et al., Lancet 2023
• CT-388 Phase 2 data presented by Roche/Carmot at ADA 2024 and ENDO 2024

Figures from this analysis

Outputs produced

• strategic_synthesis.json

  Full CT-388 SWOT analysis (5S/4W/4O/4T), strategic differentiation thesis, and Phase III trial design recommendations (BALANCE-1/2/CVOT/MASH) — primary deliverable for writing agent

• 07_strategic_synthesis.py

  Script that compiles SWOT analysis and Phase III recommendations from all upstream datasets

• 06_generate_visualizations.py

  Script generating 5 publication-quality charts for portfolio strategy review

• 05_compile_efficacy_data.py

  Curated Phase II/III clinical efficacy dataset (weight loss %) for semaglutide, tirzepatide, retatrutide, CT-388

• clinical_efficacy.csv

  Full efficacy dataset: 10 trial records with Drug, Trial_Name, Phase, Population, Trial_Design, Duration_Weeks, Dose, Mean_Weight_Loss_Pct, Placebo_Weight_Loss_Pct, Placebo_Adjusted_Weight_Loss_Pct, Notes (v2 methodology-corrected)

• clinical_efficacy_summary_std_nonT2D.csv

  Head-to-head summary restricted to Standard-design Non-T2D trials (1 row per drug, best placebo-adjusted WL) — direct input for bar chart visualization

• pipeline_data.csv

  Clinical pipeline data for 8 GLP-1/GIP agonist drugs (phase, mechanism, route) from ClinicalTrials.gov

• pharmacology_data.csv

  Binding affinity data (EC50, Ki) for GLP-1R and GIPR from ChEMBL + curated literature